What are the evidence‑based long‑term medical management strategies for a patient who has suffered a hemorrhagic stroke?

Long-Term Medical Management of Hemorrhagic Stroke

Blood pressure control is the single most critical long-term intervention after hemorrhagic stroke, with a target of <130/80 mmHg, and should be initiated immediately and maintained indefinitely. 1

Blood Pressure Management (Highest Priority)

Target BP: <130/80 mmHg long-term 1

• Begin BP control immediately after ICH onset (Class I, Level A)
• This is the strongest evidence-based intervention for preventing recurrent hemorrhage
• Lifestyle modifications are beneficial: limit alcohol to ≤2 drinks/day, tobacco cessation, avoid illicit drugs, treat obstructive sleep apnea 1

Common Pitfall: Many clinicians hesitate to aggressively lower BP after hemorrhagic stroke fearing cerebral hypoperfusion. The evidence clearly supports intensive BP lowering without increased adverse outcomes.

Antithrombotic Therapy Decision Algorithm

This is the most complex and controversial aspect of long-term management. The decision depends on the indication for antithrombotics and hemorrhage location:

For Patients with Atrial Fibrillation:

Lobar ICH (likely amyloid angiopathy):

• Avoid warfarin indefinitely (Class IIa, Level B) 1, 2
• The recurrence risk is too high (relatively high risk of recurrence with warfarin-associated lobar ICH)
• Consider left atrial appendage closure as alternative 3

Deep (non-lobar) ICH:

• Anticoagulation may be restarted, particularly with high thromboembolic risk (CHADS₂ ≥4 or mechanical heart valve) 1, 2
• Wait at least 4 weeks before restarting in patients without mechanical valves (Class IIb, Level B) 1
• DOACs (dabigatran, rivaroxaban, apixaban) have uncertain benefit/risk - insufficient data (Class IIb, Level C) 1

For Patients Requiring Antiplatelet Therapy:

Aspirin monotherapy can be restarted within days after ICH when there are strong indications (Class IIa, Level B), though optimal timing is uncertain 1

Key consideration: The risk stratification for recurrent ICH includes:

1. Lobar location (highest risk)
2. Older age
3. Microbleeds on gradient echo MRI (number matters)
4. Ongoing anticoagulation
5. APOE ε2 or ε4 alleles 1

Common Pitfall: Clinicians often permanently discontinue all antithrombotics after any ICH. The evidence suggests antiplatelet monotherapy can be considered, especially for non-lobar hemorrhages with strong cardiovascular indications.

Statin Therapy

Continue statins in most patients - there are insufficient data to recommend restrictions (Class IIb, Level C) 1

The controversy:

• SPARCL trial showed increased ICH risk with high-dose atorvastatin
• However, meta-analysis of 91,588 patients found no significant ICH association (OR 1.08,95% CI 0.88-1.32)
• Statins were associated with early neurological improvement and reduced 6-month mortality in one retrospective study
• Risk appears higher with lobar ICH and in presence of cortical microbleeds

Practical approach: Continue statins unless the patient has lobar ICH with multiple cortical microbleeds. The cardiovascular and recurrent ischemic stroke prevention benefits likely outweigh risks in most patients.

Risk Factor Management

Diabetes and Hyperlipidemia Assessment: Recent evidence shows systematic evaluation during hospitalization is suboptimal 4. Ensure:

• LDL-C measurement during admission
• HbA1c measurement during admission
• Appropriate treatment intensification for abnormal values

Comorbidity Surveillance:

• Monitor for hyperlipidemia and diabetes - these impact recurrence risk and cardiovascular events 4
• Address modifiable cerebrovascular risk factors systematically

Venous Thromboembolism Prophylaxis

Intermittent pneumatic compression should be used in immobile patients with ICH 5

Pharmacologic DVT prophylaxis timing remains controversial - balance thrombotic risk against hemorrhage expansion risk in the acute phase.

What NOT to Do

1. Do NOT use dual antiplatelet therapy (aspirin + clopidogrel) for routine secondary prevention - increases hemorrhage risk without stroke benefit 6
2. Do NOT use corticosteroids for cerebral edema management 7
3. Do NOT restart warfarin early (<4 weeks) without compelling indication 1
4. Do NOT avoid all antithrombotics reflexively - individualize based on hemorrhage location and thromboembolic risk 2, 3

Rehabilitation

Stroke unit care with comprehensive rehabilitation should be standard 3, 5. Early multidimensional rehabilitation programs improve functional and psychosocial outcomes 8.

Monitoring and Follow-up

• Regular BP monitoring to maintain target <130/80 mmHg
• Assess for recurrent symptoms
• Consider gradient echo MRI to evaluate for microbleeds if anticoagulation is being considered
• Screen for depression, sleep disturbance, and fatigue - these are common and treatable 8

The evidence base for hemorrhagic stroke is weaker than for ischemic stroke, but the 2015 AHA/ASA guidelines 1 and 2022 update 9 provide the most authoritative framework. The key is aggressive BP control and careful risk-stratification for antithrombotic decisions.